In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. Adrianzen Herrera explains the study's results and how they can be used to design future research around treatments targeting cardiovascular health in MDS.
After receiving hematopoietic stem cell transplantation (HSCT), many survivors experience issues with sexual dysfunction which can impact their quality of life. To address this challenge, Dr. Areej El-Jawahri, Director of the Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital (MGH), and her team developed a multimodal mobile app as an intervention for sexual health concerns after transplant. After presenting this research at the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. El-Jawahri sat down with Oncology Data Advisor to further explain the app's development and efficacy, as well as additional ways it can be used to improve quality of life for transplant survivors in the future.
In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Adrian Mosquera Orguiera, Clinical Hematologist at the University Hospital of Santiago de Compostela, about his research team's novel machine learning model that incorporates patient characteristics and histological subtype into risk prognostication for mantle cell lymphoma (MCL). In addition, Dr. Mosquera shares more of his research utilizing artificial intelligence for designing more risk-tailored therapeutic approaches and facilitate personalized medicine in hematologic malignancies.
At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!
In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.
At the recent American Society of Hematology (ASH) Annual Meeting, Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute, sat down with Oncology Data Advisor to share his passion for improving diversity in multiple myeloma clinical trials. He discusses the efforts that are currently underway to increase diverse accrual and the importance of raising awareness in order to address this issue both within the community and on a global scale.
CLL Society is a patient-centric, physician-curated nonprofit organization that prioritizes patient education, advocacy, and research for the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) community. Dr. Brian Koffman co-founded the organization after being diagnosed with CLL in 2005, and he currently serves as Executive Vice President and Chief Medical Officer. He recently attended the American Society of Hematology (ASH) Annual Meeting to acquire the latest CLL research to bring back and disseminate to patients, and while there, he sat down with Oncology Data Advisor to share more about the educational and advocacy work that the society does, updates in CLL research being presented at the meeting, and how patients with CLL can become more involved and empowered in their treatment and care.
In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Annemiek Broijl, Hematologist at Erasmus MC Cancer Institute in the Netherlands, discusses the IsKia trial, of which she is the Co-Primary Investigator, and its unique primary end point of measurable residual disease (MRD).
Patients with hematologic malignancies undergoing hospitalization for hematopoietic cell transplantation experience significant psychological distress, and they cope in different ways. In this interview from the 2023 American Society of Hematology (ASH), Dr. Richard Newcomb, Instructor of Medicine at Harvard Medical School, discusses his presentation on coping mechanisms employed by patients who are preparing for transplantation and ways that health care providers can help support their patients during this time.
In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Greg Knight, MD, Clinical Assistant Professor of Medicine at Levine Cancer Institute, about his presentation on the impacts of nurse navigation and other supportive care services for reducing socioeconomic disparities in acute lymphoblastic leukemia (ALL) treatment. Additionally, Dr. Knight describes Levine Cancer Institute's Financial Toxicity Tumor Board, the first program of its kind, and shares advice for how other centers can implement similar interventions for mitigating socioeconomic disparities experienced by their patients.
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more! Oncology Data Advisor® · Oncology D...
In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Alex Boucher, Director of the Pediatric and Adult Sickle Cell Programs at the University of Minnesota Medical School, about his presentation on racial discrepancies in the use of stigmatizing language in hematology/oncology electronic medical records. Dr. Boucher explains the impact that stigmatizing language can have on patient care and ways to raise awareness for mitigating its use.
In this interview from the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Andre Goy, Chair of the John Theurer Cancer Center and Hackensack University Medical Center, about his presentation on an expanded access study of brexucabtagene autoleucel (brexu-cel) for patients with mantle cell lymphoma who were ineligible for the ZUMA-2 and ZUMA-18 studies. Additionally, Dr. Goy shares insights into the growing arsenal of therapies for patients with high-risk mantle cell lymphoma.
In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Andrew Hantel, Instructor in Medicine at Harvard Medical School, shares more about his presentation on oncologists' perspectives on ethical implications of artificial intelligence (AI) in cancer care, as well as ongoing efforts build a framework for the integration of AI into oncology care delivery.